publication venue for
- Mortality Benefit in the Compass Trial: is It Related to Superior Statistical Power Or Better Efficacy and safety?. 17:175-182. 2021
- Rivaroxaban for the Prevention of Major Adverse Cardiovascular Events in Patients with Coronary or Peripheral Artery Disease. 16:597-611. 2020
- Andexanet Alfa for Reversal of Factor Xa Inhibitors: A Critical Review of the Evidence. 15:395-404. 2019
- Rivaroxaban for Prevention and Treatment of Venous Thromboembolism. 15:63-77. 2019
- Low-dose Rivaroxaban Plus Aspirin for the Prevention of Cardiovascular Events: an Evaluation of COMPASS. 14:443-453. 2018
- Clinical Implications of Reversal Agents for Direct Oral Anticoagulants. 13:153-159. 2017
- Management Considerations in the Care of Elderly Heart Failure Patients in long-term Care Facilities. 10:563-577. 2014
- Betrixaban (PRT054021): pharmacology, Dose Selection and Clinical Studies. 10:43-52. 2014
- Translating Genomic Analyses into Improved Management of Coronary Artery Disease. 6:507-521. 2010
- Point-of-care Testing for Assessment of Adequacy of Oral Antiplatelet Therapy in Patients With Cardiovascular Disease. 6:289-299. 2010
- Current and Future Uses of Candesartan in the Treatment of Heart Failure. 2:391-402. 2006